What is Neurohacking? – Neurohacker Collective

The term hacker has its origins in computer programming subcultures from the 60s, and was used to describe people who wanted to take on hard problems in a spirit of playful exploration and a resistance to unearned authority. Although the methods, means and intentions of hackers varied widely, all seemed to share a unique ethos that mixed a deep commitment to individual autonomy and agency with an equally deep commitment to collaboration and co-creation.

Over time, the concept of hacking has traveled far from its origins, finding its way into a number of domains like Biohacking, Consciousness Hacking, Flow Hacking and Life Hacking. Each is a kind of hacking because each shares this hackers ethos and a commitment to using it to find the most effective ways to optimize the human experience.

We call the common thread that links these hacking communities together, empowered responsibility. This notion expresses the dual recognition that we are no longer able to rely on external authorities to take care of us (in any domain) but through a combination of ubiquitous information, individual experimentation and open collaboration, we are increasingly empowered to take responsibility for ourselves.

In the Biohacking community, the spirit of empowered responsibility drives the process of optimizing ones biological health and performance. Biohackers learn from each other how they can modify their nutrition, exercise, sleep, movement, and mindset to achieve the specific kind of well-being that they individually desire.

The Consciousness Hacking community takes empowered responsibility in using technology as a catalyst for psychological, emotional and spiritual flourishing. They utilize mindfulness techniques and biofeedback tools for self-exploration, taking personal responsibility for their conscious experience in this most individual of journeys.

Emerging from within and alongside these movements, we are observing the coalescence of a new and important domain: Neurohacking.

Whereas biohacking concentrates on the body, and consciousness hacking explores the inner experience, neurohacking is somewhere in the middle, focusing on the mind-brain interface - the intersection of neurology and consciousness. Specifically, neurohacking involves applying science and technology to influence the brain and body in order to optimize subjective experience.

The desired outcomes of neurohacking cover everything from focused productivity, to expanded creativity, more restful sleep, reduced anxiety, enhanced empathy, and anything else that contributes to the psychological well-being and emotional health of whole, thriving human beings.

The technologies of neurohacking run the gamut from chemical technologies like nootropics and entheogens, probiotics to support the gut-brain connection, bioelectrical technologies like neurofeedback and transcranial stimulation, photic therapies like low level laser therapy and all the way to embodied practices like somatics and meditation. So long as there is a scientifically accessible biological mechanism for effecting subjective experience, it belongs in the domain of neurohacking.

Of course, like all emergent phenomena, neurohacking didnt just come from nowhere. For years there have been many movements and communities out there, playing in and pioneering some aspect of the neurohacking space.

Some of these domains include:

We propose that it is now timely and useful to perceive the commonality among these different movements and communities as shared aspects of Neurohacking. And in an effort to make these commonalities more visible and legible to each other, in the upcoming weeks we will take a deeper dive into each, highlight some notable people and projects in each space and explore the frontiers of the community from the point of view of Neurohacking.

In our next post, we will begin this exploration with the domain of Nootropics.

Originally posted here:

What is Neurohacking? - Neurohacker Collective

Neurohacking: Rewiring Your Brain by Don Vaughn …

Don Vaughn at TEDxUCLA

Following is the full text of Don Vaughns talk titled Neurohacking: rewiring your brain at TEDxUCLA conference.

Don Vaughn TEDx Talk TRANSCRIPT

Inside each one of us is a beautiful symphony. 100 billion neurons firing in concert, constructing this vivid reality that were living in. And inside each little piece of that neural activity lives a little bit of what makes you, you.

And after your experiences today, that activity will have shifted and you will never be the same. You are inextricably tied to your brain.

When I first learned these principles, when I was 16, I fell in love with the brain, and Ive been doing neuroscience research ever since.

Now, one day, we were doing a new MRI experiment. And I was surprised because the experiment went well, but much to all of our shock, I had a hole in my brain. It was a pretty big one too; it was like 30% of my cerebellum just wasnt there.

Which, as you might imagine, I was pretty shocked because I didnt feel like anything about me or my life and my experience of the world had changed or was missing.

The cerebellum is one of the most fundamental parts of your brain. It has, like, 80% of all of your neurons. So I got interested.

Now, theres this collision between what your brain is supposed to do and then what its dealt, and somehow it finds a middle ground. And I became really interested in the idea of your brain as a dynamic, flexible system.

And to that end, I want to tell you the story of Cameron Mott. Just after her third birthday, Cameron started having violent seizures. They started becoming worse and worse, and eventually, she was losing her ability to speak.

Doctors diagnosed her with something called Rasmussens encephalitis, and the only real treatment for this was a hemisphererectomy cutting out half of her brain. And keep in mind that one half of your brain controls and is responsible for movement and sensation in the other half of your body.

So this surgery would immediately leave Cameron hemiplegic. But just four weeks post-op, she walked out of the hospital. And she is still dealing with a bit of hemiplegia and a bit of peripheral vision loss. But otherwise, she is able to run around with her peers, and she is cognitively quite deft its amazing.

And I wondered, you know consider that for a second: if I gave you half of a car, or half of a phone, you wouldnt be going anywhere in LA, and you wouldnt be on Twitter right now tweeting about how mind expanding TEDxUCLA is.

Because for most devices, 50% equals broken. But somehow in this instance with Cameron, 50% is almost equal to 100%.

HOW IS THAT POSSIBLE?

Well, the remaining part of Camerons brain sensed the massive loss of neural tissue, and it physically rewired and reorganized itself to take over everything that the other half had previously handled. That is an ability known as neuroplasticity. Its the ability of the brain to change itself to rewire.

And so, I think its not a very good analogy when people say your brain is like a computer. Its actually just a really bad one because your brain is not static hardware.

And although the prevailing view in neuroscience for a long time was that the adult brain is a fixed processing unit, it seems like every day we find a new result that says thats not the case at all.

While there is structure to your brain, it is dynamic, flexible biology. Let me say that again: You and your brain are static, but youre also dynamic you can change yourself.

So the idea worth spreading is this: What if we were able to treat injuries and impairments in an entirely new way, by hacking into your brains ability to rewire itself.

To show you what I mean, lets look at how weve treated depression.

Since 1952, scientists and doctors have addressed the question of treatment for depression as a fixed hardware problem where there is a deficiency of happy neurotransmitters, like serotonin, dopamine, norepinephrine.

And in this context, it makes perfect sense that the way to go about it is to discover and design drugs which increase those neurotransmitter levels. Enter MAOIs, tricyclics, SSRIs there are hundreds of them, but they all work in pretty much the same way.

And these are marvels of modern medicine. I mean, on anti-depressants, we see about two-thirds of people see some sort of symptom relief. But that still leaves 1.5 million people, in the US alone, who are still struggling to enjoy their lives, who are becoming disconnected from their friends and their families. It is an awful, debilitating disease.

So what if we were able what would become possible if we addressed the problem from the perspective of neuroplasticity? So what were doing is were essentially finding regions in the brain that show different activation in depressed patients than in normals.

So for example, if someone with depression shows dorsolateral prefrontal cortex it is not as active as it is in other brains we actually use electromagnetic currents from devices placed on the scalp to induce neural rewiring in those areas.

Read more:

Neurohacking: Rewiring Your Brain by Don Vaughn ...

Election Lawyer Calls On Trump Supporters To Stock Up On ‘Second Amendment Supplies’ – HuffPost

The fringe right-wing lawyer who filed the court challenge toDonald Trumps election loss in Georgia has called on the presidents supporters to stock up on Second Amendment supplies presumably firearms and ammunition to prepare for what he apparently envisions as an apocalyptic future.

Our leader is Donald Trump, not Biden, attorney Lin Wood tweeted Sunday.

Make sure you have PLENTY of water, food, flashlights & batteries, candles, radio, 2nd Amendment supplies, & a plan to meet with leaders of your communities, he urged. He included a photo of Trump with the caption: Im still your president.

A reporter for the right-wing Newsmax site piped up in a tweet that when Lin Wood tells people to prep, I listen.

Wood has called on Trump to declare martial law in a bid to wrest the White House from the electorate. The lawyers theory is that Americans working with Venezuela, China, Serbia, Canada, Venezuela, Cuba, the CIA, billionaire philanthropist George Soros, the Clinton Foundation, and state and local officials from both parties rigged the presidential election.

Wood has filed several lawsuits challenging Joe Bidens win, including one in his home state of Georgia, which was touted by Trump before it went down to defeat.

Wood said at a press conference earlier this month that Trump called to tell the attorney he knows he won this election. The president said, Lin, I didnt lose it. I won it, Wood recounted.

Several Twitter followers mocked Woods call to stock up for an armageddon, with one checking on vodka storesand another urging people to getmarshmallows for smores.

Others heard a call to arms. One wondered when the FBI would show up at Woods door to question him about instigating violence,

Calling all HuffPost superfans!

Sign up for membership to become a founding member and help shape HuffPost's next chapter

Follow this link:

Election Lawyer Calls On Trump Supporters To Stock Up On 'Second Amendment Supplies' - HuffPost

The Fifth Day of Christmas, Brought to You by Bloomberg and Beto-Backed Texas Lawmakers – NRA ILA

NRA-ILA is counting down the legislativelumps of coal that anti-Second Amendment lawmakers in Texas are leaving in gun owners' stockings this year.

The 2021 Texas legislative session is less than a month away.Please support NRA-ILA as we work withgun ownersto STANDYOUR GROUND on your Second Amendmentrights at theCapitol in Austinnext year!

Next up:House Bill 238 by Rep. TerryMeza (D-Irving), which repeals thestate firearms preemption law, allowingcities and counties to regulate gunsand ammunition in any manner they see fit.

Municipalities like Austin, Dallas, El Paso, Houston, and San Antonio could be free to enactgun bans, magazine limits, licensing and registration schemes, andprohibitions on carrying firearmson your person or in your car.Only five states -- CT, HI, MA, NJ & NY, allbastions of gun control -- have no preemption protection.Preemption ensures uniformity in state gun laws so that honestcitizens aren't subject toconfusing and conflicting localrestrictions or denied their Second Amendment rights based on where they live, work or travel.

The importance of preemption was highlighted back in March during the early stages of COVID-19, as city and county officials adopted emergency ordersclosing most businesses, including gun stores.Attorney General Ken Paxon ruled inOpinion No. KP-0296that these local orders could notregulate or restrict the sale of firearms, and he relied heavily on Texas'firearms preemption statute in his opinion.

NRA-ILA has worked nearlyevery legislativesession to improve Texas' firearms preemption law and furtherprotect your rights.Wewilloppose any attempt to repeal or weaken it in the 2021 legislative session.

Here is the original post:

The Fifth Day of Christmas, Brought to You by Bloomberg and Beto-Backed Texas Lawmakers - NRA ILA

Buckeye Firearms Association Wants Answers In Casey Goodson Jr. Shooting – WOSU

A column published by one of Ohio's most powerful gun rights organizations says Second Amendment supporters should demand answers about the shooting death of a Black man in Columbus.

Franklin County Sheriff's deputy Jason Meade shot and killed 23-year-old Casey Goodson Jr.on December 4, claiming he was waving a handgun. Goodson's family says he was holding a bag of sandwiches and unlocking the door of his home. Law enforcement says Meade never mistook a sandwich for a gun.

While hundreds of people have rallied in downtown Columbus demanding answers, Chad Baus with the Buckeye Firearms Association believes gun owners should be seeking those answers as well.

I am encouraging Second Amendment rights people to join in the call that we get all the facts and we get a fair and impartial investigation in this thing, because Casey deserves that as much as any other concealed handgun licensed holder, he says.

Goodson did possess an up-to-date concealed carry license. Sean Walton, a lawyer representing Goodson's family, said Goodson eagerly educated his family about gun safety and laws.

Baus says that people who advocate for gun rights can be hesitant to weigh in on police-involved shootings.

Were very pro-law enforcement. We realize that the law enforcement officers are trying to keep us safe thats why they exist, he says. So oftentimes the Second Amendment community seems really hesitant to speak into these situations too soon, because we dont have all the information.

Baus says the shooting brings to light questions surrounding the right to legally carry a gun and a person's skin color.

There are many people who are concerned about even being able to exercise their Second Amendment right because of the color of their skin and because of their fears about how that interaction could go if they have to interact with law enforcement, he says.

Baus notes this is not the first time a Black man, licensed to carry a gun, has died at the hands of law enforcement. He thinks its an issue the entire community needs to address.

We are one big family, we always like to talk about that, so lets be a big family and lets talk about [the fact] that part of our family is suffering, he says.

Read the original:

Buckeye Firearms Association Wants Answers In Casey Goodson Jr. Shooting - WOSU

NRA Takes Concealed Carry Case to the Supreme Court – NRA ILA

FAIRFAX, Va.- The National Rifle Associations Institute for Legislative Action (NRA-ILA) has partnered with the New York State Rifle and Pistol Association (NYSRPA) today to ask the Supreme Court to hear a challenge to New Yorks restrictive process for issuing concealed carry licenses.

"As long as New York continues denying law-abiding gun owners their Second Amendment rights, the NRA will continue fighting to protect and expand those rights," said Jason Ouimet, executive director of NRA-ILA.

The case, NYSRPA v. Corlett, challenges New York's requirement for applicants to demonstrate "proper cause" to carry a firearm. While New York routinely employs this arbitrary standard to deny carry permits, the NRA argues that this right should be available to "all 'the people'" instead of a "subset of the people that can distinguish themselves from their fellow Americans by showing proper cause.

The NRA is the leader in Americas right-to-carry movement having pioneered the effort on legislative and legal fronts since the 1980s. Today, due to its efforts, more than 40 states have what the NRA describes as "shall-issue" laws where states are required to give residents who apply and satisfy prerequisites their requested permits. The NRA is also the national leader in the "constitutional carry" movement where law-abiding residents in 16 states do not require a permit to carry a firearm. This is the second lawsuit the NRA and NYSRPA have brought to the High Court in as many years. The move is just the latest in NRAs decades-long fight to protect and expand Americans right to carry.

Eventually, these anti-freedom activists will understand that our Second Amendment right to keep and bear arms is fundamental, and it doesnt vanish when we leave our homes. Until then, we will continue these battles wherever they arise," concluded Ouimet.

See original here:

NRA Takes Concealed Carry Case to the Supreme Court - NRA ILA

QuickLogic Announces the Amendment and Extension of Credit Facility – PRNewswire

SAN JOSE, Calif., Dec. 16, 2020 /PRNewswire/ --QuickLogic Corporation (NASDAQ: QUIK) ("QuickLogic" or the "Company"), a developer of ultra-low power multi-core voice enabled SoCs, embedded FPGA IP, and Endpoint AI solutions, today announced that, effective December 11, 2020, it entered into a second amendment (the "Second Amendment") to its amended and restated credit facility, dated as of December 21, 2018 (as amended, the "Credit Agreement") to extend the maturity date and decrease the interest rate.

The Second Amendment extends the maturity date from September 28, 2021 to September 28, 2022. The previous interest rate was the greater of (i) 0.50% above the Prime Rate or (ii) 5.50%. The Second Amendment reduces the interest to be equal to 0.50% above the Prime Rate.

"We are pleased to extend our credit facility at a reduced rate and appreciate the continued support of Heritage Bank of Commerce to allow us to focus on operating the business. The maturity extension and interest rate improvement are expected to provide both an immediate benefit while supporting our long-term growth objectives as we focus on achieving profitability before the end of 2021," said Chief Financial Officer Sue Cheung.

Additional details on the terms of the amendment are available in the 8-K filed with the Securities and Exchange Commission on December 16, 2020.

About QuickLogic

QuickLogic is a fabless semiconductor company that develops low power, multi-core semiconductor platforms and Intellectual Property (IP) for Artificial Intelligence (AI), voice and sensor processing. The solutions include an embedded FPGA IP (eFPGA) for hardware acceleration and pre-processing, and heterogeneous multi-core SoCs that integrate eFPGA with other processors and peripherals. The Analytics Toolkit from the Company's wholly-owned subsidiary, SensiML Corporation, completes the end-to-end solution with accurate sensor algorithms using AI technology. The full range of platforms, software tools and eFPGA IP enables the practical and efficient adoption of AI, voice and sensor processing across the multitude of mobile, wearable, hearable, consumer, industrial, edge and endpoint IoT applications. For more information, visitwww.quicklogic.com andhttps://www.quicklogic.com/blog/.

QuickLogic uses its website (www.quicklogic.com), the company blog(https://www.quicklogic.com/blog/), corporate Twitter account (@QuickLogic_Corp), Facebook page (https://www.facebook.com/QuickLogic), and LinkedIn page (https://www.linkedin.com/company/13512/) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and QuickLogic may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor the Company's website and its social media accounts in addition to following the Company's press releases, SEC filings, public conference calls, and webcasts.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, expectations regarding our future business, and actual results may differ due to a variety of factors including: delays in the market acceptance of the Company's new products; the ability to convert design opportunities into customer revenue; our ability to replace revenue from end-of-life products; the level and timing of customer design activity; the market acceptance of our customers' products; the risk that new orders may not result in future revenue; our ability to introduce and produce new products based on advanced wafer technology on a timely basis; our ability to adequately market the low power, competitive pricing and short time-to-market of our new products; intense competition by competitors; our ability to hire and retain qualified personnel; our ability to capitalize on synergies with our newly acquired subsidiary SensiML Corporation; changes in product demand or supply; general economic conditions; political events, international trade disputes, natural disasters and other business interruptions that could disrupt supply or delivery of, or demand for, the Company's products; the unpredictable and ongoing impact of the COVID-19 pandemic; and changes in tax rates and exposure to additional tax liabilities. These and other potential factors and uncertainties that could cause actual results to differ materially from the results contemplated or implied are described in more detail in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the risks discussed in the "Risk Factors" section in the Company's Annual Reports on Form10-K, Quarterly Reports on Form10-Q and in the Company's prior press releases, which are available on the Company's Investor Relations website athttp://ir.quicklogic.com/, and on the SEC website atwww.sec.gov. In addition, please note that the date of this press release is December 16, 2020, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements as a result of new information or future events.

QuickLogic and the QuickLogic logo are registered trademarks of QuickLogic Corporation. All other brands or trademarks are the property of their respective holders and should be treated as such.

CODE: QUIK-E

SOURCE QuickLogic Corporation

Home

Original post:

QuickLogic Announces the Amendment and Extension of Credit Facility - PRNewswire

St. Louis Prosecutor Removed From Case Involving Gun-Brandishing Couple – NPR

St. Louis Circuit Attorney Kim Gardner is the city's first Black Circuit Court attorney. On Thursday a circuit judge disqualified her and her staff from prosecuting the case against Mark McCloskey. Christian Gooden/St. Louis Post-Dispatch/Tribune News Service via Getty Images hide caption

St. Louis Circuit Attorney Kim Gardner is the city's first Black Circuit Court attorney. On Thursday a circuit judge disqualified her and her staff from prosecuting the case against Mark McCloskey.

The St. Louis prosecutor spearheading the case against Mark McCloskey, one half of the husband-and-wife team accused of menacing Black Lives Matter protesters with weapons, has been removed from the case.

Circuit Judge Thomas Clark II on Thursday dismissed Circuit Attorney Kim Gardner and her entire staff, saying campaign fundraising emails Gardner sent to constituents that alluded to Mark and Patricia McCloskey's case "raise the appearance of impropriety and jeopardize the defendant's right to a fair trial," The Associated Press reported.

The ruling means Gardner can no longer oversee McCloskey's prosecution. Instead, a special prosecutor will have to be selected to take over. The decision does not apply to McCloskey's wife, Patricia, who is scheduled to appear before a different judge on Jan. 15.

The couple's defense attorneys filed the motion to disqualify Gardner in July, arguing it was an unprecedented move for a prosecutor to discuss a case in campaign materials, NBC affiliate KSDK reported. Court documents note the materials were sent out as early as three days before Gardner had filed any criminal charges against his clients.

Attorney Joel Schwartz wrote, "The July 17th email drew a direct line from the incident, which had not yet resulted in criminal charges, to Ms. Gardner's political antagonists and from there to a call for donations to further her re-election efforts."

The McCloskeys, who are white, became a polarizing couple over the summer when they brandished firearms at a crowd of marching protesters; Mark McCloskey waved around an AR-15 rifle while Patricia kept her finger on the trigger of a handgun as a few hundred protesters marched toward the home of St. Louis Mayor Lyda Krewson.

The couple insist they believed the protesters, who they say had torn down a fence to enter the gated community, would have burned down their mansion if the two hadn't "stood their ground."

They were indicted in October on charges of unlawful use of a weapon and tampering with evidence. Both have pleaded not guilty.

The confrontation was captured on video and has drawn ire from Black Lives Matter supporters and praise from Second Amendment activists. It has also stoked the heated debate over the rights and protections of protesters.

Gardner, who is St. Louis' first Black Circuit Court attorney, says the emails referenced the McCloskey case in an effort to defend herself from backlash from conservative politicians and media.

"Kim needs your help to fight back!" one campaign email read, according to the AP. She added that she was under "national scrutiny from our divisive President, the Republican establishment of Missouri, and the right-wing media, including Fox News."

But KSDK notes that in his 22-page ruling Thursday, Clark wrote: "Ms. Gardner has every right to rebut criticism, but it appears unnecessary to stigmatize defendant or even mention him in campaign solicitations, especially when she purports to be responding to others.

"In fact, the case law and Rules of Professional Conduct prohibit it," Clark added.

Go here to read the rest:

St. Louis Prosecutor Removed From Case Involving Gun-Brandishing Couple - NPR

Hanks announces advisory council and committees – Post Register

(BOISE) On Thursday, Dec. 3, new State Representative Karey Hanks (R-St.Anthony) and 103 other Idaho legislators took their oath of office at the organizational session of the Sixty-sixth Idaho Legislature in the Boise Capitol. (One legislator was ill and unable to attend.)

I am thankful to return as a representative and serve the people of District 35, and the people of Idaho, Hanks said. I felt that awesome, humble feeling as we were sworn to uphold the Idaho and U. S. Constitutions. It is such an honor and responsibility to serve our constituents well.

Hanks will serve on State Affairs, Agriculture, and Commerce and Human Resources committees representing Fremont, Jefferson, Butte and Clark counties.

I look forward to serving on my three assigned committees, she said. Agriculture is my first choice, where I have some experience and knowledge. The State Affairs committee handles second amendment bills, as well as pro-life and other statewide issues. The Commerce committee addresses unions, wages and retirement issues.

Additionally, Hanks has assembled a Legislative Advisory Council to assist in determining or qualifying the benefits and/or consequences to proposed legislation.

This advisory council includes: Greg Bitter (motorsports), Brad Orme (retail petroleum sales/hotel), Sandy Edwards (commercial trucking/farming), Dr. Jason West (medical), Chip Schwarze (commerce), Shane Berger (banking), Collette Rinehart (marketing consultant), Kenneth J. Babcock (insurance), Dr. Drostan Orme (dental), and Dan Babcock (heavy-duty towing/auto body).

I have received very positive responses to my invitation to our district business people, as well as a few others in our region, to advise me in their areas of expertise, Hanks said. This will be of benefit to myself and those I serve, in casting the most informed votes possible.

She anticipates expanding this council with additional community and business leaders. The 2021 Legislative session begins Jan. 11 in Boise, including an address from Governor Brad Little.

Read more from the original source:

Hanks announces advisory council and committees - Post Register

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid…

DURHAM, N.C. and BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures. Founding investors Hatteras Venture Partners and the Foundation Fighting Blindness RD Fund, along with existing investors Osage University Partners, University of Florida, and Manning Family Foundation, also participated in the round. Sarah Bhagat, PhD, Partner at Sofinnova, Jackie Grant, PhD, Principal at Abingworth, and Jason Lettmann, General Partner at Lightstone, will join Atsenas board of directors.

Proceeds will be used to advance Atsenas ongoing Phase I/II clinical trial evaluating a gene therapy for patients with GUCY2D-associated Leber congenital amaurosis (LCA1), one of the most common causes of blindness in children, as well as complete manufacturing development for Phase 3. In addition, the funds will enable Atsena to expand its team to support the research and development of novel gene therapies, including the progression of two existing preclinical programs in inherited retinal diseases toward the clinic and advancement of the companys innovative adeno-associated virus (AAV) technology platform.

We are grateful for the support of our new and existing investors and are encouraged by their enthusiasm for the potential of our technology to overcome the unique hurdles of inherited retinal diseases to prevent or reverse blindness, said Patrick Ritschel, MBA, Chief Executive Officer of Atsena. The Series A financing provides financial runway to reach the key inflection point of reading out efficacy data from our LCA1 clinical trial. While we continue expeditiously advancing this trial and our preclinical programs, we are excited to accelerate our growth as a leading ophthalmic gene therapy company.

The Phase I/II LCA1 clinical trial is currently enrolling patients in the second dosing cohort. Atsena exclusively licensed the rights to the gene therapy from Sanofi, which originally licensed it from University of Florida. LCA is the most common cause of blindness in children. LCA1 is caused by mutations in the GUCY2D gene and results in early and severe vision impairment or blindness. GUCY2D-LCA1 is one of the most common forms of LCA, affecting roughly 20 percent of patients who live with this inherited retinal disease.

We believe Atsenas foundation in ocular gene therapy and potentially game-changing novel AAV vectors position the company to become a partner of choice, said Dr. Bhagat. Sofinnova is delighted to support Atsena and we look forward to helping the team further its mission to develop life-changing gene therapies for patients with inherited retinal diseases.

About Atsena TherapeuticsAtsena Therapeutics is a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness. The companys ongoing Phase I/II clinical trial is evaluating a potential therapy for one of the most common causes of blindness in children. Its additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease, and its unique approach is guided by the specific needs of each patient condition to optimize treatment. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye, Atsena has a licensing, research and manufacturing collaboration with the University of Florida and has offices in Boston, MA and North Carolinas Research Triangle, environments rich in gene therapy expertise. For more information, please visit atsenatx.com.

About Sofinnova InvestmentsSince our founding in 1974, Sofinnova has been active in life science investing. We are a clinical-stage biopharmaceutical investment firm with approximately $2.3B in assets under management and committed capital. We invest in both private and public equity of therapeutics-focused companies. Our goal is to actively partner with entrepreneurs in both the U.S. and Europe, across all stages of company formation. From drug development and navigating the regulatory process to company building and IPO, we strive to be collaborative, meaningful board members, and excellent partners at every level. We seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately, the lives of patients. Sofinnova has expertise investing in gene therapy companies, including investments in Spark, which developed the first approved gene therapy, Akouos, and Audentes, and Xylocor. For more information, please visit http://www.sofinnova.com.

About Abingworth Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in approximately 168 life science companies, leading to more than 44 M&A/exits and close to 70 IPOs. Our therapeutic focused investments fall into 3 categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California) and Boston. For more information, visit abingworth.com.

About Lightstone VenturesLightstone Ventures is a leading venture capital firm investing in therapeutic-oriented companies across the life science spectrum, from breakthrough medical devices to novel drugs and biopharmaceuticals. Founded in 2012, Lightstone has been part of many successful new ventures from inception through commercialization and plays a critical role guiding and building successful healthcare companies. With a proven strategy and global footprint, the Lightstone team has been involved in several of the largest venture-backed life science exits over the last decade including: ALX Oncology, Acceleron, Ardian, Calithera, Claret Medical, Disarm, MicroVention, Nimbus, Plexxikon, Portola, Promedior, Proteolix, Ra Pharma, Tizona, Twelve and Zeltiq. For more information, visithttps://www.lightstonevc.com.

Read more:

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid...

Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and…

SAN DIEGO, Dec. 14, 2020 /PRNewswire/ --Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, today announced a $100 million Series B financing. The financing was led by Vida Ventures with participation from new investors including RA Capital Management, Invus, Acuta Capital Partners and an investment fund associated with SVB Leerink and prior Locanabio investors ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures and GV.

"This financing positions us to accelerate our efforts to advance multiple promising programs into IND-enabling studies in 2021 and to further develop our novel RNA-targeting platform, which has the potential to be a major new advance in medicine that can bring hope to patients with many devastating genetic diseases," said Jim Burns, Ph.D., chief executive officer at Locanabio. "We are pleased that a team of highly sophisticated investors led by Vida Ventures has joined in this financing round, further validating our progress in research and the significant potential of our unique RNA-targeting platform."

The financing will advance Locanabio's portfolio of RNA-targeted gene therapies and expand the technology platform to pursue a broad range of therapeutic indications. Locanabio is currently developing therapies to treat multiple genetic diseases with no approved therapeutic alternatives, including Huntington's disease, spinocerebellar ataxia type 1, myotonic dystrophy type 1, genetic forms of amyotrophic lateral sclerosis and retinal diseases.

The Company also announced that Rajul Jain, M.D., director of Vida Ventures, will join Locanabio's board of directors. Prior to joining Vida, Dr. Jain, a physician-scientist by background, was on the executive team and headed development for Kite Pharma, a Gilead company, and previously was global development lead for Amgen.

"The unique approach in RNA targeting using gene therapy to deliver RNA binding proteins developed by Locanabio represents the next frontier of genetic medicine with the ability to target the root cause of a range of genetic diseases," said Dr. Jain. "They have built a strong management team to execute this bold vision and we are proud to support them."

About Locanabio, Inc.

Locanabio is the global leader in developing a new class of genetic medicines. Our unique and multi-dimensional approach uses gene therapy to deliver RNA binding protein-based systems to correct the message of disease-causing RNA and thereby change the lives of patients with devastating genetic diseases. These broad capabilities delivered via gene therapy enable Locanabio to potentially address a wide range of severe diseases with a single administration. The company is currently advancing programs in neurodegenerative, neuromuscular and retinal diseases. For more information, visit http://www.locanabio.com.

Contacts

Company ContactMicah MackisonChief Business OfficerLocanabio, Inc. [emailprotected]

Media ContactJenna UrbanBerry & Company[emailprotected]+1-212-253-8881

SOURCE Locanabio, Inc.

http://www.locanabio.com

More here:

Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNA-Targeted Gene Therapies for Neurodegenerative, Neuromuscular and...

NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 -…

In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts

Findings provide support for hypothesized mechanism of action of anti-gene, which is designed to not degrade the DMPK transcript

Data further validate the potential of the PATrOL platform to develop highly targeted therapies that increase, decrease or change causal protein function

NeuBase management to hold conference call and webcast today, December 16, at 8:00 a.m. EST

PITTSBURGH, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBases anti-gene approach to comprehensively treat the underlying cause of DM1.

Despite the fact that the genetic basis of DM1 is well understood today, there is still an urgent need to find the first genetically-targeted, disease-modifying treatment option for affected patients, said Curt Bradshaw, Ph.D., Chief Scientific Officer of NeuBase. DM1 is caused by a genetic mutation in the DMPK gene leading to mis-splicing of a broad spectrum of genes and DMPK protein insufficiency. A treatment option that addresses mis-splicing while retaining functional DMPK protein levels may be key to treating all aspects of DM1.

Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, added, Using our proprietary PATrOL platform, we have designed a first-in-class anti-gene candidate that selectively binds mutant DMPK mRNA and opens its hairpin secondary structure, as opposed to a mechanism of action that explicitly degrades the mutant and wild-type transcripts indiscriminately, making it a unique option for the treatment of DM1. These in vitro and in vivo data both support our hypothesized mechanism of action and demonstrate rapid and broad resolution of the mis-splicing that is the primary cause of DM1.

This is the second set of positive data that weve announced in 2020 for our PATrOL-enabled therapies, which we believe serves as proof of concept that further validates our technologic foundation. With a single unified platform, we believe we can increase, decrease or change protein function of potentially any nucleic acid target, unique among genetic medicine approaches. We are excited by the progress we have made and look forward to providing additional updates on our platform and pipeline of programs at an R&D day in the first half of 2021.

In vitro data highlights in DM1 patient-derived fibroblasts:

In vivo data highlights in the HSALR transgenic mouse model of DM1 that expresses high levels of mutant CUG-repeat-containing mRNA (HSA) in skeletal muscle:

DM1 is a rare, autosomal dominant repeat expansion disorder characterized by progressive muscle wasting and weakness. It also affects the central nervous system (CNS) and heart. DM1 is caused by CTG nucleic acid repeats in the DMPK gene that produce a hairpin structure in the transcribed DMPK mRNA. The hairpin structure sequesters critical splice regulators and results in the mis-splicing of multiple gene transcripts. Furthermore, the binding of splice regulators traps the mutant DMPK mRNA in the nucleus, resulting in DMPK protein haploinsufficiency, or half the level of protein that is needed for normal function, which is thought to exacerbate the CNS and cardiac symptoms that are characteristic of DM1 (as knock-out mice for Dmpk show both severe cardiac conduction defects as well as issues with neuronal cytoskeletal remodeling manifesting in aberrant long-term potentiation). The prevalence of DM1 is >5/100,000 in the general population. There are currently no approved treatments for DM1.

Conference Call and Webcast Details

NeuBase Therapeutics, Inc. will discuss these data during a webcasted conference call with slides today, December 16, 2020, at 8:00 a.m. EST. To access the webcast, please click here. An archived recording of this presentation will be available following the call through the IR Calendar page on the Investors section of the Companys website, http://www.neubasetherapeutics.com.

About NeuBase Therapeutics, Inc.NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase's designer PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit http://www.neubasetherapeutics.com.

Use of Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to the potential significance and implications of the Companys positive in vitro and in vivo preclinical data for its PATrOL-enabled anti-gene therapies for the treatment of myotonic dystrophy. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company's plans to develop and commercialize its product candidates; the timing of initiation of the Company's planned clinical trials; the risks that prior data will not be replicated in future studies; the timing of any planned investigational new drug application or new drug application; the Company's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company's product candidates; the Company's commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com OP: (617) 430-7576

NeuBase Media Contact:Cait Williamson, Ph.D.LifeSci Communicationscait@lifescicomms.com OP: (646) 751-4366

Excerpt from:

NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 -...

Genetic Analysis Services Market: Uptake of Next-generation Sequencing and Multi-gene Tests to Drive Market – BioSpace

Genetic Testing to Establish Strong Foothold in Current and Future Healthcare System

The notable rise in the demand for hereditary genetic testing over the past few years is one of the major factors that is expected to fuel the growth of the global genetic analysis services market in the upcoming decade. Technological advancements coupled with the drive to discover new and innovative genetic analysis techniques are set to shape the overall growth trajectory of the global genetic analysis services market during the forecast period. Over the past decade, the genome testing sector has witnessed consistent developments due to which, the global genetic analysis services market is anticipated to expand at an impressive rate during the assessment period.

Read Report Overview - https://www.transparencymarketresearch.com/genetic-analysis-services-market.html

Hereditary genetic testing has emerged as ideal, and a rapidly evolving technology within the genetic analysis services market. This is likely to continue, owing to advancements in technology and findings of research activities. The increasing demand for improved and cutting-edge prediction and diagnostic tools and services coupled with surge in demand for disease monitoring is anticipated to play a key role in the overall growth of the global genetic analysis services market during the assessment period.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2555

Healthcare experts and credible researchers around the world are of the opinion that genetic testing is expected to be the future of the healthcare ecosystem. Advancements in the biomedical field coupled with the notable rise in the number of companies that are developing new genetic-testing kits are expected to augment the global genetic analysis services market during the forecast period. Moreover, as interest levels for precision medicine continues to witness sizeable growth around the world, as a result of which the demand for genetic analysis services is projected to grow at an impressive pace.

Request for Analysis of COVID-19 Impact on Genetic Analysis Services Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2555

Uptake of Next-generation Sequencing and Multi-gene Tests to Drive Market

Advancements in the genetic technology are likely to play an instrumental role in shaping the growth trajectory of the global genetic analysis services market during the forecast period. Furthermore, due to advancements in technology, the scope of genetic testing has widened by a considerable margin due to which, the demand for genetic analysis services is increasing. While genetic analysis services in the past were largely time-consuming and cumbersome, at present, increasing speed and availability of genomic testing are anticipated to present a plethora of opportunities to the players involved in the current market landscape for genetic analysis services.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2555

In addition, the gradual shift in the point of access to testing is evolving, as more number of consumers can avail genetic analysis services outside the healthcare setting. Advancements in genetic medicine at the back of advancements in technology are likely to bolster the growth of the global genetic analysis services market during the assessment period.

Pre Book Genetic Analysis Services Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=2555&ltype=S

Research and Development Activities in Full Swing amid COVID-19 Pandemic

Research and development activities are expected to continue in full swing amid the ongoing COVID-19 pandemic. The significant rise in the demand for genetic counseling services during the ongoing COVID-19 crisis is anticipated to generate consistent revenue for the players involved in the genetic analysis services market. Furthermore, researchers and scientists are increasingly focusing on discovering genetic mechanisms that are required to prevent the spread and transmission of the novel coronavirus disease. Genetic research is estimated to unlock various intricate details of the novel coronavirus, thereby opening up new opportunities for mitigation. The ongoing research pertaining to genetics and its correlation with the ongoing pandemic is expected to provide a detailed and microscopic understanding of the overall cellular mechanisms of the virus.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See the rest here:

Genetic Analysis Services Market: Uptake of Next-generation Sequencing and Multi-gene Tests to Drive Market - BioSpace

FDA Clears Genetic Modification in Pigs for Biomedicine and Food – The Scientist

The US Food and Drug Administration granted approval yesterday (December 14) for a genetically modified line of pigs that marks the first time a GM animal has been given the regulatory greenlight for both therapeutic development and food consumption, the agency says in a statement. The alteration knocks out alpha-gal, a sugar molecule on the surface of cells, and could help minimize allergic reactions to pork and reduce the risk of organ rejection in transplant patients.

The move represents a a tremendous milestone for scientific innovation, FDA Commissioner Stephen Hahn says in the statement. The FDA strongly supports advancing innovative animal biotechnology products that are safe for animals, safe for people, and achieve their intended results.

Pigs with the genetic modification are known as GalSafe pigs and are made by Revivicor Inc, a subsidiary of the US biotech United Therapeutics. Research in the mid-2010s indicated that the knockout made transplants from the pigs less likely to be rejected by primate recipients.

The director of the FDAs Center for Veterinary Medicine, Steven Solomon, told reporters in a conference call yesterday that developers who want to use GalSafe pigs for therapeutic purposes will still have to seek approval for their applications. I think that people need to be careful, Solomon said, STATreports. Thats why in part, its going to require further evaluation for xenotransplantation, xenograft, or the other activities by the medical products centers and FDA.

As far as food production is concerned, the statement notes that the meat is safe for consumption by the general population, adding that Revivicor intends to sell meat from GalSafe pigs by mail order, rather than in supermarkets.

The agencys evaluation also concluded that GalSafe pigs presented low risk to the environment, with an impact that is no greater than from conventional pigs. It adds that no animal safety concerns were noted for GalSafe pigs beyond those that would be expected in well-managed, commercial swine populations.

Multiple other efforts to develop genetically engineered pigs are underway around the world, including some alterations designed to make pigs grow faster, and others aimed at making the animals more resistant to lethal viruses such as porcine reproductive and respiratory syndrome virus (PRRSV).

Excerpt from:

FDA Clears Genetic Modification in Pigs for Biomedicine and Food - The Scientist

Key Genes Related to Severe COVID-19 Infection Identified – The Scientist

More than a year after the first cases of COVID-19 were detected, researchers are still trying to understand why some people infected with the virus become critically ill, while others have little to no symptoms. Scientists have turnedto look at the genes of patients with severe COVID-19 to understand if their bodies mount an immune defense differently than healthy patients do. A genome-wide association study published in Natureon December 11 finds that variants of five key genes responsible for antiviral immunity and lung inflammation are associated with severe COVID-19.

The findings offer potential therapeutic targets to create an effective COVID-19 treatment. Our results immediately highlight which drugs should be at the top of the list for clinical testing, Kenneth Baillie, a consultant in critical care medicine and a senior research fellow at the University of Edinburgh, tells Reuters.

Baillie and his colleagues analyzed the DNA of 2,244 patients across 208 UK intensive care units and compared it to matched controls who did not have a positive COVID-19 PCR test on file. They identified eight loci where variants were more common among the intensive care patients, of which five were in genes linked to the immune systemIFNAR2, TYK2, OAS1, DPP9, and CCR2.

An analysis looking into the relationship between the activity of certain genes and severe COVID-19 pointed to a lower expression of IFNAR2, a gene that encodes a building block of a receptor for interferons, which act as emergency flares to warn the immune system of an intruder and have been a target for researchers hoping to develop a COVID-19 treatment. However, administering interferon to hospitalized COVID-19 patients did not reduce mortality, according to a large clinical trial published earlier this month.

The researchers also homed in on a possible link between severe COVID-19 and higher expression levels of TYK2and CCR2, which encode proteins used in cytokine signaling, which drives inflammation and can lead to lung injury. The anti-inflammatory drug baricitinib, typically used to treat rheumatoid arthritis, inhibits the protein encoded by the TYK2gene and has shown promising results in treating COVID-19 when paired with remdesivir, a broad spectrum antiviral that has shown limited effectiveness against the virus by itself, according to a study published December 11 in The New England Journal of Medicine.

While the Naturestudy may offer clues for the genetic underpinnings of severe COVID-19 infection, finding an effective treatment in humans may still be years away. There is no guarantee that when a gene is found, targeting that gene will result in therapeutic efficacy, Tom Hemming Karlsen, a physician at the University of Oslo who did not participate in the new work, tells The Washington Post. What genetics studies like this then do is they help us find very specific starting points for further investigation.

The authors' investigation indicated that there is a causal role for IFNAR2 and TYK2. Sara Clohisey, a research fellow at the University of Edinburgh and a coauthor of the Nature study, notes that there are likely many other factors beyond these gene variants that contribute to COVID-19 disease severity.

A chunk of the answer is in our genes, but its unlikely that a single element is fully responsible for the development of severe COVID-19, she tells the Post. Its more likely to be a combination of factors, which may include genetics as well as age, obesity, gender, and other characteristics.

Correction (December 15): A previous version of this article misinterpreted Sara Clohisey's comments about the causality of her findings.The Scientistregrets the error.

Read more:

Key Genes Related to Severe COVID-19 Infection Identified - The Scientist

UNLV Researcher on the Curious Case of COVID-19 Reinfection – UNLV NewsCenter

Once youve had COVID-19, youre safe from getting it again, right?A northern Nevada man learned the hard way earlier this year that getting re-infected with COVID-19 soon after surviving it just might be possible. After testing positive in April, the man subsequently tested negative multiple times until becoming ill just 48 days later and testing positive again in June.To figure out what was going on, scientists from the Nevada State Public Health Laboratory at the University of Nevada, Reno, along withUNLV researcher Richard Tillett with the Nevada Institute of Personalized Medicine, looked deeper into the genetic blueprint of the mans virus samples and found differences between the two cases.In other words, he was infected twice.Thankfully, reinfection looks to be pretty uncommon, says Tillett. And I hope that it remains that way.Still, the work conducted by Tillett and colleagues uncovered the first confirmed case of a person reinfected with the virus in North America. Their research was published in the prestigious medical journal The Lancet InfectiousDiseases in October.

The scientific community in Nevada and beyond has rallied together like never before to uncover the many mysteries of COVID-19.Tillett, a biostatistician, joined UNLV in August after working with the Nevada Center for Bioinformatics in Reno. He studies the genome or building blocks of disease, and his work with the Nevada Institute of Personalized Medicine is now squarely focused on finding ways to conquer COVID-19.We spoke with Tillett to learn more about the likelihood of COVID-19 reinfection, the teams landmark study, whats next, and his advice for what we can all do to keep ourselves and our loved ones safe.

My role in this study was to analyze the virus genomes collected from this patient from his earlier and later positive tests, compare the genomes to one another and to genomes in circulation, and finally, either find evidence that the two viruses differed or rule it out.

We identified the man, a Washoe County resident, as a part of our effort to survey SARS-CoV-2 genomes across Nevada. With both public health labs in the state providing samples, corresponding author Dr. Mark Pandori, director of the Nevada State Public Health Lab with the University of Nevada, Reno, was able to identify the man.

We started with a basic set of facts in the testing history. We knew that the patient had tested positive via the PCR test, which is used to diagnose active infection. He had symptoms, then improved. He subsequently had two negative tests, indicating his infection was over. Then six or seven weeks after his first positive test, he felt sick again, got tested again, and was again positive.Now, PCR test results like these are only suggestive of re-infection. In order to confirm reinfection, we needed to sequence the viral genomes from both positive tests. When we obtained those genome sequences, we found six differences between the virus in the samples, by which we were able to rule out alternative scenarios such as it being one long infection.

Honestly, I felt fright. We had to be sure we were right if we were going to claim proof that the possibility of reinfection was more than possible, but had actually happened for this person.

Currently, reinfection looks to be pretty uncommon. And I hope that it remains that way. Though we don't yet know how long an average person may have lasting immunity to SARS-CoV-2, less than a year into this pandemic, it currently looks like reinfection is not the norm.

My advice is to stay vigilant. Wear masks. Social distance. Avoid gatherings. Wash your hands. And if you feel like you maybe haven't been doing a great job at enacting these suggestions, this is too important to beat yourself up over. Remember that its not too late to start or restart lowering your exposure risk.

The research community here in Nevada, the U.S., and globe are doing great work together in response to the pandemic and have embraced collaboration and knowledge-sharing to help tackle this threat. Our hope is that continued study will help us understand this virus, track it, monitor unfolding outbreaks, and keep guard in the future, even after vaccines become widely available.

At the Nevada Institute of Personalized Medicine, my colleagues including Professor Edwin Oh and I are continuing to track and study COVID-19 genomes from Nevada patient samples.Weve begun a major effort to detect SARS-CoV-2 in wastewater, and once detected, identify the mixture of mutations found in the viruses in that wastewater. This work will give us a tremendous amount of new information on the burden and spread of this virus in the community complementary to and beyond patient samples.

Read more from the original source:

UNLV Researcher on the Curious Case of COVID-19 Reinfection - UNLV NewsCenter

Genomics and medicine it’s complicated | Health | willistonherald.com – Williston Daily Herald

In a truly grand feat of modern science, The Human Genome Project, an international collaborative effort, set out in 1990 to map our genetic makeup using diverse human genetic samples. In 2003 the project was completed, ultimately showing about 20,000 human genes. Since that projects completion, with ever-improving DNA sequencing technology, genomics researchers continue to gather more and more information about human DNA.

A single human cell contains a mind-numbing 6 billion base pairs (each base pair is one of four types of nucleic acid molecules) in its DNA, organized into 23 pairs of chromosomes. Fascinatingly, only about 1.5 percent of our DNA actually codes for proteins, while the vast remainder is noncoding DNA, serving a regulatory function or, at least as far as we understand, no function at all.

In 2007 the first individual human genome was sequenced and published. In 2008, James Watson (as in, the 1962 Nobel Prize winning Watson and Crick model of the DNA double helix) poetically had his genome sequenced and published. The ability to sequence an individual humans genome held much promise, we hoped, in regard to predicting illness and personalizing medical interventions. But in 2020, this promise remains very much unfulfilled. In most cases primary care physicians dont yet utilize genomics information in our daily practice. Why is this?

The short answer: Its complicated. In some specific instances, genetic information can clearly convey an increased risk for disease. One example of this might be the BRCA gene mutation and associated risk of future breast or ovarian cancer. Because this specific gene mutation is so tightly linked with elevated risk, testing and finding the mutation in an individual (based on their family history or known relative with a mutation) can have direct practical implications on strategies for cancer screening or even consideration of surgery to remove the at-risk tissue.

Scenarios like BRCA mutation are outliers, however. When we look to common diseases, such as cardiovascular disease or diabetes, finding genetic information useful gets, well, complicated. In these cases, what we have found is that many genes are involved, and it is extremely difficult to estimate how much a mutation in one of those genes affects overall risk. Thats not to mention all the environmental factors which may affect risk as much or more than the genetic profile.

Genomics remains a vast, new, and thus-far difficult to access specialty of medicine. At its current rate of growth, however, I am confident my previous statement will not remain true during my career in medicine.

Kelly Evans-Hullinger, M.D. is part of The Prairie Doc team of physicians and currently practices internal medicine in Brookings, South Dakota. For free and easy access to the entire Prairie Doc library, visit http://www.prairiedoc.org and follow Prairie Doc on Facebook, featuring On Call with the Prairie Doc a medical Q&A show streamed most Thursdays at 7 p.m. central.

Excerpt from:

Genomics and medicine it's complicated | Health | willistonherald.com - Williston Daily Herald

Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases – PRNewswire

PALO ALTO, California, Dec. 16, 2020 /PRNewswire/ --Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with Illumina Inc. and the integration of automated interpretation into Illumina's TruSight Software Suite for rare genetic diseases. Emedgene's Clinical Rare Disease application is one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases.

Healthcare is in the midst of a leap towards precision medicine.Continued improvements in the cost of next-generation sequencing (NGS) technologies, such as those developed by Illumina, have dramatically accelerated the adoption of genetic testing. Consequently, data generated from genomics doubles every year and is expected to reach 20 exabytes by 2025. The genomic interpretation market transforms data into meaningful insights that improve patient care and impact the many different medical disciplines that incorporate genomics into routine care.

As next generation sequencing has become readily accessible throughout the globe, data interpretation of sequencing outputs has struggled to keep pace. Gaining insights can require hours of manual review. Machine learning offers the opportunity to automate and speed the process, uncover new insights and provide additional context to researchers in a shorter time.

Emedgene's Cognitive Genomics IntelligenceTM solution automatically produces insights from genomic data, reducing the time and cost of its interpretation. High-value features within Emedgene's AI solution are now integrated into Illumina's TruSight Software Suite platform. With AI-enhanced interrogation of medical literature and phenotypes associated with rare disease, researchers are positioned to make new and unexpected discoveries.

"In the future, patients will have access to the $100 genome, making it as ubiquitous as a blood test. This genomic data will be attached to an electronic medical record, and inform clinical decision making throughout our lives. Billions of patients across disease areas will benefit from faster diagnosis and better treatment. Illumina has initiated the precision medicine revolution by unlocking the power of the genome. Emedgene is on a mission to equip healthcare and lifesciences organizations challenged to practice precision medicine, by making genomic insights accessible to all. We're tremendously enthusiastic about the scale our new partnership with Illumina will enable, and the number of patients that will benefit from a genetic diagnosis," said Einat Metzer, Emedgene's Co-Founder and CEO.

"It's essential that we deliver best-in-class tertiary analysis capabilities that complement our platforms which is why we have chosen to work with Emedgene on the integration of their AI tools into TruSight Software Suite," says Ryan Taft, VP, Scientific Research at Illumina. "The combination of Illumina's comprehensive analysis of the genome with Emedgene's AI-driven insights will allow our customers to identify disease-causing variants at-scale, reducing interpretation time and benefiting individuals with rare genetic disorders across the globe."

AboutEmedgene:Emedgene is on a mission to unlock genomic insights for the world's health organizations by providing data-driven AI solutions for genomic diagnostics and discovery at scale. We work with leading healthcare and lifesciences organizations to enable precision medicine programs, enable high throughput diagnostics and accelerate the pace of research. To learn more, visit http://www.emedgene.com

Read more at http://www.emedgene.com.

SOURCE Emedgene

https://emedgene.com/

Read the original post:

Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases - PRNewswire

Polymerase Chain Reaction Market | Increased Outbreak of Infectious Diseases to Accentuate Demand in the Market – BioSpace

The growth of the global polymerase chain reaction market is likely to be driven by its growing utilization in various clinical diagnostics, increasing demand for precision and personalized medicine. In addition, growing application in the development of drugs and technological progress is likely to work in favor of the global polymerase chain reaction market over the timeframe of analysis, from 2019 to 2029.

In the last few years, personalized medicine has gained increasing popularity due to its ability to offer tailor-made therapies to patients. Personalized medicines come with a high margin of safety and promise of offering improved patient care and lower the overall cost of healthcare. The increasing demand for personalized medicines is likely to generate immense opportunities for the genetic medicines. There is a growing need for the development of novel technologies, which can be utilized for the purpose of expansion of the global polymerase chain reaction market. In an attempt to attain competitive edge in the rising field of personalized medicine, pharmaceutical and biotechnological companies are exploring the grounds of direct-to-consumer genetic testing and genomic medicine. These factors are likely to foster growth of the global polymerase chain reaction market over the period of assessment, from 2019 to 2029.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7029

Product, end user, and region are the three significant parameters based on which the global polymerase chain reaction market has been categorized. The main purpose of such segmentation is to offer a lucid and detailed view of the said market.

Global Polymerase Chain Reaction Market: Notable Developments

The global polymerase chain reaction market is marked with presence of quite a few prominent players and it is considered moderately competitive market for both the existing players and new entrants. These companies are entering into partnerships, collaborations, and mergers in an effort to gain larger revenue and share of the market.

Some of the key players in the global polymerase chain reaction market comprise the below-mentioned:

Global Polymerase Chain Reaction Market: Key Trends

The below-mentioned market dynamics are estimated to characterize the global polymerase chain reaction market over the assessment period, from 2019 to 2029.

The development of the global polymerase chain reaction market is likely to gather momentum with the outbreak of Covid-19 across the globe. In an effort to facilitate growth of personalized medicine, it is essential to come up with reproducible and precise tool of gaining information about molecule about underlying conditions. Such developments are likely to guide correctly the clinical decision making abilities with a large number of tests making use of PCR techniques. All these factors are likely to pave way for growth of the global polymerase chain reaction market over the timeframe of analysis, from 2019 to 2029.

In addition to Covid-19, outbreak of infectious diseases, such as Zika has generated increased demand for PCR-based molecular assays. This technique is gaining increased importance for the purpose of identification of pathogens of these infectious diseases, which is why the demand for polymerase chain reaction is likely to rise in the years to come.

Global Polymerase Chain Reaction Market: Geographical Analysis

North America is expected to dominate the growth of the global polymerase chain reaction market over the timeframe of analysis, from 2019 to 2027. Growth of the North America is ascribed to the presence of flexible regulatory guidelines and favorable government initiatives, Asia Pacific is likely to come up as rapidly growing region in the global polymerase chain reaction market. Improvement in the healthcare infrastructure and increased expenditure on healthcare industry is expected to propel growth of the Asia Pacific market in the years to come.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7029

The global polymerase chain reaction market is segmented as:

Product

Application

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read the original here:

Polymerase Chain Reaction Market | Increased Outbreak of Infectious Diseases to Accentuate Demand in the Market - BioSpace

LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors – BioSpace

LEXINGTON, Mass., Dec. 14, 2020 /PRNewswire/ --LogicBio Therapeutics Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company developing therapies based on advanced gene editing technology and next-generation synthetic capsids, today announced that Daphne Karydas and Jeff Goater have been appointed to the Company's board of directors.

"We are excited to welcome Daphne and Jeff. They both bring an impressive depth of experience and proven leadership in the areas of corporate finance, global strategic planning, mergers and acquisitions and strategic partnerships in the biopharma sector," said Frederic Chereau, LogicBio president and CEO. "As we plan for many major developments at LogicBio including initiation of our phase 1/2 SUNRISE clinical trial for LB-001, we believe their expertise will play a central role in guiding our corporate strategic planning and help us reach new levels of momentum in all operational areas."

Ms. Karydas is chief financial officer at Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Previously, she served as senior vice president of corporate financial planning & analysis and strategy at Allergan plc, where she oversaw financial and business strategy through the company's acquisition by Abbvie in May 2020. Prior to joining Allergan, Ms. Karydas spent over 17 years in asset management and investment banking focused on the bio-pharmaceutical sector. She served as a senior healthcare analyst at J.P. Morgan Asset Management and a portfolio manager and senior healthcare analyst at The Boston Company Asset Management and was a vice president at Goldman Sachs Asset Management and a member of Goldman Sachs' healthcare investment banking team. She began her career as a project chemical engineer at Merck & Co. and earned a B.S. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

Mr. Goater is chief executive officer at Surface Oncology, an immuno-oncology company developing next-generation antibody therapies. Previously he was chief financial officer of Voyager Therapeutics, helping to guide the company through an initial public offering and establishment of a strategic partnership with Sanofi Genzyme. For almost ten years he was an investment banker, most recently at Evercore Partners where he was an advisor on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist and earned master's degrees in microbiology/immunology, pathology and business administration from the University of Rochester.

"I am especially excited to be joining the LogicBio board of directors as the Company plans for a range of promising product development milestones and business opportunities based on the potential of the platform," said Ms. Karydas. "I look forward to working with the team to expand the Company's progress and target new opportunities in the rapidly emerging gene editing space."

"In recent years, LogicBio has made significant progress both in advancing its pipeline and in positioning the Company for many promising opportunities in research and business development," said Mr. Goater, adding, "I look forward to joining with the other members of the board in helping the Company achieve its mission of bringing innovative therapies to patients with rare diseases around the world."

"As we welcome Daphne and Jeff to our board, we also are very grateful to Erez Chimovits and Daniel O'Connell, who are stepping down from our board, for their service during several formative and active years for our Company," Mr.Chereau added.

About LogicBio Therapeutics

LogicBio Therapeuticsis dedicated to extending the reach of genetic medicine with pioneering platforms. LogicBio's proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio has received FDA clearance for the first-in-human clinical trial of LB-001, a wholly owned genome editing program leveraging GeneRide for the treatment of methylmalonic acidemia. Patient enrollment in the phase 1/2 SUNRISE clinical trial is expected to begin in early 2021. In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome.

LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples. Top-tier capsid candidates from this effort have demonstrated significant improvements over benchmark AAVs currently in clinical development. LogicBio is developing these highly potent vectors for internal development candidates and potentially for business development collaborations.

Forward Looking Statements

This press release contains "forward-looking" statements within the meaning of the federal securities laws. These are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available. They are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress and results of the Company's current and future research and development activities and preclinical studies and potential future clinical trials. These risks are discussed in the Company's filings with theU.S. Securities and Exchange Commission(SEC), including, without limitation, the Company's Annual Report on Form 10-K filed onMarch 16, 2020, the Company's Quarterly Report on Form 10-Q filed on May 11, 2020, and the Company's subsequent filings with theSEC. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Media contact:Jenna UrbanBerry & Company Public Relationsjurban@berrypr.com212 253 8881

View original content:http://www.prnewswire.com/news-releases/logicbio-therapeutics-names-daphne-karydas-and-jeff-goater-to-board-of-directors-301191719.html

SOURCE LogicBio Therapeutics, Inc.

Read more:

LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors - BioSpace